Singapore: Australian biopharmaceutical company Imugene has appointed Dr Christoph Zielinski and Dr Ursula Wiedermann to...
Singapore: Living Cell Technologies have signed an agreement with Otsuka Pharmaceutical Factory to co-develop NTCELL for...
Singapore: The US Food and Drug Administration (FDA) has accepted Australia-based CSL Behring's biologics license applic...
Singapore: Victorian Minister for Technology, Mr. Gordon Rich-Phillips, has launched a Guide for Life Science Company Di...
Entry of multinational companies has been a big boost to Asia's position in biologics manufacturing, especially with cGM...
Singapore: A team of Australian researchers, led by University of Melbourne has developed a genetic test that is able to...
Singapore: Australia-based Living Cell Technologies (LCT) has implanted regenerative cell therapy NTCELL, a treatment fo...
Singapore: Gilead Sciences' phase II study (Study 101-08) evaluating idelalisib (formerly GS-1101), an investigational, ...
Singapore: AusBiotech calls on the Federal Government to provide some certainty to the innovation sector as support pro...
Singapore: The US Food and Drug Administration (FDA) has set August 26, 2013, as the date for action on QRxPharma's res...
Melbourne-based bluechiip is a tracking technology company that was listed on the Australia Stock Exchange in June 2011....
Singapore: Analysis from leading healthcare fund manager BioScience Managers has highlighted the outstanding year for bi...
Singapore: The Australian government has joined hands with generics manufacturer Apotex in suing Sanofi Aventis seeking ...
The fifth edition of the annual BioSpectrum Asia Pacific clinical research organization (CRO) Survey, which is conduct...
Singapore: Melbourne-based drug delivery technology company, Phosphagenics, is going to launch phase I study of a transd...
Singapore: Australian schoolboys have begun receiving the first-of-three vaccinations to protect them against cancers a...
Singapore: Patrys has received approval to commence its planned phase I/IIa multiple myeloma trial with lead anti-canc...
